Events

Horizon Europe Info Day on EU Missions - 2026 call topics
JAN
Tue
20
JAN
Wed
21

Starts in 2 months from now

Location

online

Programmes
Health Climate, Energy, Mobility Agro-Food, Environment Missions

The European Commission will hold an online info day about the 2026 call topics of the EU Missions work programme 2026 - 2027. You can find all the details via this link

You will have the opportunity to engage and ask questions with Slido, before the event and during the sessions.

Background: EU Missions are commitments to bring concrete solutions to some of the greatest challenges facing our world. They are an integral part of the Horizon Europe framework programme. There are 5 missions in total

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.